Loading
Five years on, the higher radiotherapy dose still controlled indolent lymphoma far better: 90 percent of treated sites were free of regrowth after 24 Gy against 70 percent after 4 Gy.
Long-term follow-up of the FoRT trial (614 target sites in 548 patients) at a median of 73.8 months: 117 local progression events, 27 after 24 Gy and 90 after 4 Gy.
Local progression-free rates were 94.1 percent at two years and 89.9 percent at five years after 24 Gy against 79.8 and 70.4 percent after 4 Gy (hazard ratio 3.46).
Confirms 24 Gy in 12 fractions as the optimal dose for indolent lymphoma when durable local control is the goal.
Shares FoRT, FORTplus, Marginal zone lymphoma, The Lancet Oncology.
Shares Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03, FORTplus, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares FORTplus, Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares Marginal zone lymphoma, The Lancet Oncology, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.